A quiet but potentially life altering gap in cancer genetics has come to light. Researchers in Denmark and Australia have identified four unrelated patients with constitutional methylation of the MLH1 promoter, a rare genetic anomaly that mimics Lynch syndrome but evades standard diagnostic protocols. Unlike typical Lynch syndrome, which stems from inherited mutations in mismatch repair genes, this condition arises from epigenetic silencing of MLH1, a gene critical for DNA repair. The findings, published in *European Journal of Human Genetics*, reveal that these patients developed cancers not traditionally linked to Lynch syndrome, including breast cancer and a benign dermal tumor, complicating diagnosis and risk assessment for families.
Clinical Significance
Lynch syndrome is one of the most common hereditary cancer predispositions, increasing the risk of colorectal, endometrial, and other cancers. Typically, it is caused by inherited mutations in mismatch repair genes like MLH1, MSH2, MSH6, or PMS2. However, constitutional methylation of the MLH1 promoter, a form of epigenetic silencing, accounts for 5 to 10 percent of Lynch like cases where no germline mutation is detected. This condition is particularly insidious because it produces a clinical picture indistinguishable from classic Lynch syndrome, yet it is often dismissed as a sporadic tumor due to the presence of MLH1 methylation, a hallmark of non hereditary cancers.
Deep Dive and Research Findings
The study, led by researchers at Aarhus University Hospital and Royal Melbourne Hospital, examined four patients with constitutional MLH1 methylation, none of whom had detectable germline mutations in the MLH1 promoter. The patients exhibited a striking diversity of tumors, including colorectal, endometrial, and breast cancers, as well as a benign dermal lipofibroma, none of which are classically associated with Lynch syndrome. This variability underscores the challenge of identifying affected individuals based solely on clinical presentation.
Methylation levels in non cancerous tissue ranged from 2 to 40 percent, with two patients showing evidence of mosaicism, where methylation is present in only a subset of cells. Mosaicism complicates risk assessment, as lower methylation levels may correlate with a milder phenotype, though the study’s first patient, with just 2 percent methylation, developed aggressive colorectal cancer at age 24. The findings suggest that even low level methylation can drive severe disease, though the exact threshold for clinical significance remains unclear.
One of the most concerning aspects of constitutional MLH1 methylation is its potential for transmission across generations. While the condition is not typically inherited in a dominant pattern, rare cases of mother to child transmission have been documented. This raises critical questions about family screening protocols, as relatives of affected individuals may unknowingly carry the same epigenetic risk.
Why This Discovery Matters for Patients and Clinicians
The study highlights a critical blind spot in current genetic testing protocols. Because MLH1 methylation is commonly found in sporadic tumors, clinicians often assume that its presence rules out a hereditary cause. This assumption can lead to missed diagnoses, leaving patients and their families unaware of their elevated cancer risk. The authors emphasize that systematic testing for constitutional methylation should be considered in patients under 50 with MLH1 deficient tumors or those with multiple tumors exhibiting MLH1 methylation, regardless of age.
Another key takeaway is the need for improved interpretation of methylation data. The study encountered challenges with older tissue samples, where methylation levels were unexpectedly high, possibly due to artifacts or biological variability. These inconsistencies underscore the importance of standardized testing methods and further research to refine risk stratification.
Future Outlook and Medical Implications
The discovery of constitutional MLH1 methylation as a cause of Lynch like syndrome has far reaching implications for cancer genetics. First, it expands the spectrum of hereditary cancer predispositions, necessitating updates to genetic counseling and testing guidelines. Second, it raises the possibility that other epigenetic mechanisms may contribute to cancer risk in ways that are not yet fully understood. Finally, it highlights the need for more sensitive and specific diagnostic tools to detect low level methylation and mosaicism.
For now, the authors propose a pragmatic approach to identifying at risk patients: testing for constitutional methylation in individuals under 55 with MLH1 deficient tumors or those with multiple tumors showing MLH1 methylation. This strategy could help close the diagnostic gap while minimizing unnecessary testing in low risk populations.
Patient or Practitioner Guidance
For patients with a personal or family history of early onset colorectal or endometrial cancer, particularly those with tumors showing MLH1 deficiency but no detectable germline mutation, constitutional methylation testing may be warranted. Genetic counselors should consider this possibility when evaluating Lynch syndrome cases, especially if the clinical picture includes atypical tumors like breast cancer or benign growths.
Clinicians should also be aware that methylation levels can vary widely, and even low level methylation may confer significant cancer risk. Family members of affected individuals should be counseled about the potential for inherited risk, though the exact transmission patterns remain unclear. Until more data are available, a cautious approach, including regular surveillance for at risk relatives, is advisable.
Key Takeaways
- Constitutional MLH1 methylation is a rare but significant cause of Lynch like syndrome, often misdiagnosed due to overlapping features with sporadic tumors.
- Patients with this condition may develop cancers not traditionally linked to Lynch syndrome, including breast cancer and benign tumors, complicating clinical identification.
- Methylation levels can vary widely, with even low level methylation potentially driving aggressive disease, though mosaicism adds complexity to risk assessment.
- Current genetic testing protocols may miss this condition, as MLH1 methylation is often assumed to indicate sporadic rather than hereditary cancer.
- Systematic testing for constitutional methylation should be considered in patients under 55 with MLH1 deficient tumors or multiple tumors showing MLH1 methylation.
Frequently Asked Questions
What is constitutional MLH1 methylation, and how does it differ from Lynch syndrome?
Constitutional MLH1 methylation is an epigenetic change that silences the MLH1 gene, leading to a Lynch like syndrome. Unlike classic Lynch syndrome, which is caused by inherited mutations in mismatch repair genes, this condition arises from methylation of the MLH1 promoter, which can occur without any detectable genetic mutation. The clinical presentation is nearly identical, but the underlying mechanism, and potential inheritance patterns, differ.
Why is this condition often missed in clinical practice?
MLH1 methylation is commonly found in sporadic tumors, so clinicians often assume its presence rules out a hereditary cause. This assumption can lead to missed diagnoses, as constitutional methylation, a rare but real cause of Lynch like syndrome, is overlooked. The study highlights the need for systematic testing in high risk patients to avoid this diagnostic gap.
Who should be tested for constitutional MLH1 methylation?
Testing should be considered for patients under 55 with MLH1 deficient tumors or those with multiple tumors exhibiting MLH1 methylation, regardless of age. This includes individuals with early onset colorectal or endometrial cancer, particularly if no germline mutation is detected. Family members of affected individuals may also benefit from counseling and surveillance.
Can constitutional MLH1 methylation be inherited?
While the condition is not typically inherited in a dominant pattern, rare cases of mother to child transmission have been documented. This means that relatives of affected individuals may carry the same epigenetic risk, though the exact transmission patterns are not yet fully understood. Genetic counseling is recommended for families with a history of early onset cancers.
What cancers are associated with constitutional MLH1 methylation?
Patients with this condition may develop a range of tumors, including colorectal, endometrial, and breast cancers, as well as benign growths like dermal lipofibromas. This variability makes clinical identification challenging, as some of these cancers are not traditionally linked to Lynch syndrome.
Medical Review: MedSense Editorial Board
DISCUSSION (0)
POST A COMMENT